Cystatin C: the kidney marker muscle mass can't fool

What cystatin C is and why it exists

Cystatin C is a small protein produced at a steady rate by nearly every nucleated cell in the body. The kidneys filter it from the blood through the glomeruli; if filtration slows, cystatin C rises; if filtration improves, it falls. It is freely filtered at the glomerulus, almost entirely reabsorbed and broken down by the proximal tubules, and not secreted back into the bloodstream — making it a clean, direct read on glomerular filtration rate independent of muscle mass.

How cystatin C tracks filtration without the muscle bias

Creatinine, the classic kidney marker, depends heavily on muscle turnover. A larger frame, higher muscle mass, creatine supplementation, or intense training can push creatinine up even when the kidneys are functioning normally. Cystatin C is produced at a steadier rate across body sizes, correcting that bias. Modern equations can calculate eGFR from creatinine alone, from cystatin C alone, or from both together; the combined CKD-EPI creatinine–cystatin C equation is currently considered the most accurate eGFR estimate, and it is especially useful when the two markers disagree. Cystatin C does not measure creatinine clearance — it reflects glomerular filtration independent of muscle mass.

Beyond filtration, large cohort studies link higher cystatin C and lower eGFR with higher risk of cardiovascular events and earlier mortality, even after accounting for creatinine. Filtration rate is therefore a window into vascular integrity, metabolic load, and microcirculation across the body — not just a kidney-specific signal.

Non-renal drivers complicate interpretation and are worth knowing in depth. Hypothyroidism raises cystatin C and hyperthyroidism lowers it, both independent of true GFR. Corticosteroids elevate cystatin C regardless of kidney function. Systemic inflammation and smoking also raise it through mechanisms unrelated to filtration. Labs use slightly different immunoassay platforms, though most are now standardized to international reference materials. A single value tells a story; a trend tells the plot.

Reading cystatin C and your eGFR together

Reference intervals are statistical ranges built from the population a lab serves — "normal" means you resemble most people tested there. Optimal ranges reflect associations with better outcomes in research but are not diagnoses by themselves. With eGFR, clinicians think in stages and time: a sustained eGFR below 60 mL/min/1.73 m² for three months suggests chronic kidney disease, especially when paired with albumin in the urine. The combined creatinine-plus-cystatin C eGFR is currently considered the most accurate single estimate. Age, sex, life stage, and the lab's exact assay all matter, so use your number as the start of a conversation.

High cystatin C

A high cystatin C typically means the kidneys are filtering more slowly, which lowers eGFR. That can reflect chronic kidney disease, acute illness, dehydration, or anything that reduces blood flow to the kidneys. When cystatin C and creatinine both rise together, the signal that filtration has dipped is stronger. When cystatin C rises while creatinine stays flat, non-renal influences — thyroid dysfunction, systemic inflammation, smoking, or corticosteroid use — should be considered before concluding filtration loss. Context sharpens interpretation: elevated blood pressure, albumin in the urine, a recent contrast study, a new medication, or a recent viral illness all matter. Patterns that persist across repeat tests carry more weight than one-off spikes.

Low cystatin C

Lower cystatin C usually signals better filtration and a higher eGFR, which is often reassuring. Early pregnancy can lower cystatin C due to increased kidney blood flow. Hypothyroidism can nudge it down independent of filtration. If results don't match the clinical picture — for example, low cystatin C alongside swelling and high blood pressure — assay differences or timing may be in play. Interpretation lives in the trend line and the clinical story, not just the number.

Normal cystatin C

A representative adult reference range for cystatin C is approximately 0.62–1.15 mg/L, though exact intervals vary by lab and assay platform — always interpret against the reference range provided with your result. An eGFRcys above 90 mL/min/1.73 m² generally indicates normal filtration in the absence of other kidney damage markers. Because different immunoassay platforms can yield different absolute cystatin C values even when standardized, results are most meaningful when compared within the same lab over time. The combined creatinine-plus-cystatin C eGFR remains the most accurate single estimate when both markers are available.

Factors that nudge cystatin C up or down

One of cystatin C's key advantages as a filtration marker is that it is largely unaffected by diet and exercise — unlike creatinine, which rises transiently with high protein intake, creatine supplementation, or intense training. That stability means changes in cystatin C are more likely to reflect true shifts in filtration or a specific non-renal confounder rather than lifestyle noise.

The most clinically important non-renal drivers are thyroid status and inflammation. Hypothyroidism raises cystatin C and hyperthyroidism lowers it, both independent of GFR — TSH is the first confounder to check when cystatin C and creatinine eGFRs diverge unexpectedly. Systemic inflammation, tracked by markers such as hs-CRP, can elevate cystatin C without any true drop in filtration; smoking has a similar effect. Corticosteroids raise cystatin C independent of kidney function and should be noted when interpreting any result drawn during or shortly after a course of treatment.

Several medications alter kidney markers in ways worth understanding. ACE inhibitors and ARBs lower intraglomerular pressure to protect kidneys long term, though they may cause a small initial bump in creatinine; cystatin C often stays stable during this early adjustment. NSAIDs can constrict kidney blood flow and raise both markers. SGLT2 inhibitors change kidney sodium handling and tend to improve long-term kidney outcomes in diabetes. Iodinated contrast, certain antibiotics, chemotherapy agents, and immunotherapies can affect filtration acutely. Pregnancy shifts hemodynamics and lowers cystatin C through increased kidney blood flow rather than improved filtration per se.

Factors that support stable kidney function over time — consistent physical activity improving insulin sensitivity and vascular tone, blood pressure management, glycemic control, and adequate sleep — tend to keep cystatin C and eGFR on a steady trajectory. These work through their effects on glomerular hemodynamics and systemic vascular health rather than by directly altering cystatin C production.

Cystatin C and its companion kidney markers

Cystatin C is most informative when read alongside the markers below. When results agree, confidence in the interpretation rises; when they diverge, the discordance itself is data.

• Creatinine — the complementary filtration marker; when cystatin C and creatinine eGFRs disagree, the discordance usually reflects muscle mass, thyroid status, or inflammation rather than a true filtration change.
• Blood urea nitrogen (BUN) — rises with protein load and dehydration; the BUN/creatinine ratio helps separate pre-renal from intrinsic causes of an elevated cystatin C.
• Estimated glomerular filtration rate (eGFR) — the CKD-EPI equation combining creatinine and cystatin C is the most accurate eGFR estimate; trending over 6–12 months reveals trajectory more reliably than any single value.
• High-sensitivity CRP (hs-CRP) — elevated CRP can raise cystatin C independent of kidney function; a high cystatin C with high CRP and stable creatinine may reflect inflammation rather than filtration loss.
• Thyroid-stimulating hormone (TSH) — hypothyroidism raises and hyperthyroidism lowers cystatin C independent of GFR; TSH is the first confounder to check when cystatin C and creatinine eGFRs diverge unexpectedly.

Cystatin C: a slow-marker retest window

True GFR changes slowly — kidney function typically shifts over months, not weeks. Retesting cystatin C within 8–12 weeks of a prior draw usually measures biological noise rather than a real change in filtration status; cystatin C reflects the same slowly evolving filtration trajectory as creatinine-based eGFR.

For stable CKD stages 1–3, retesting every 6–12 months is generally appropriate. For stages 4–5, or when monitoring the effect of a specific intervention, every 3 months provides a more useful trend. When comparing results over time, the same lab and the same assay platform matter — different immunoassay platforms can yield different absolute cystatin C values even when standardized to international reference materials, making cross-platform comparisons unreliable.

Timing of the draw also affects interpretation. Avoid testing during acute illness or active corticosteroid use if possible, as both temporarily elevate cystatin C independent of GFR and can make a stable filtration picture look worse than it is.

When a cystatin C result warrants a clinician's read

Measuring cystatin C alongside creatinine-based eGFR turns a fuzzy snapshot into a sharper image, especially when muscle mass or lifestyle confounders limit what creatinine alone can show. Trending these markers over time catches meaningful shifts early and puts single-visit blips in perspective.

Bring a result to a clinician when cystatin C is elevated and creatinine is not — that pattern warrants a thyroid and inflammation check before concluding filtration has declined. Act promptly when both markers rise together, when albumin appears in the urine alongside a falling eGFR, or when eGFR has been below 60 for three months or more. A brief review of medications, recent illnesses, and the assay platform used can prevent chasing the wrong problem.

A comprehensive panel that includes cystatin C, creatinine-based eGFR, and urine albumin gives the whole filtration story at once — turning isolated numbers into a coherent, personal narrative that is actionable with your clinician. Superpower's advanced biomarker testing is built on that principle: evidence-based, longitudinal, and aligned with the Superpower approach to proactive health.